CGRP Prevention as First-Line: The Guideline Versus the Step-Therapy Requirement
A newly diagnosed chronic migraine patient has two real, specific reasons to avoid both older first-line preventives at once. The debate isn't whether CGRP therapy is appropriate for her — it's whether that clinical answer and her insurance plan's own coverage rule are actually asking the same question.
E.M. grades chemistry lab reports by the stack most evenings, forty students’ worth of measured uncertainty and significant figures — work that asks for exactly the kind of sustained attention her migraines have been eating into for the better part of a year. She is 34, has taught high school chemistry for nine years, still keeps the periodic table her own tenth-grade teacher gave her taped inside a cabinet door, and was treated for a major depressive episode in her late twenties — resolved now, stable for three years on sertraline, no residual symptoms she or her psychiatrist would call active. What brought her to headache clinic is arithmetic she finally sat down and did: eighteen headache days last month, ten of them unmistakably migrainous, aura on four. She has never taken a daily preventive medication for migraine; until this year, over-the-counter naproxen was enough.
The two oral preventives with the longest track record both run into her directly. Propranolol carries real, well-documented signal for precipitating or worsening depression, not a theoretical concern in a patient three years into a remission she worked to get. Topiramate’s cognitive burden — the word-finding difficulty and processing slowdown clinicians openly nickname “dopamax” — is not a side effect she can absorb quietly; she stands in front of a classroom answering unscripted chemistry questions five periods a day. Neither drug is contraindicated in the absolute sense; both carry a specific cost that lands harder on her than on an average trial participant. The American Headache Society’s 2024 position statement (Charles et al.) moved CGRP-targeting therapies to a first-line option in their own right, on the strength of comparative data like HER-MES, where discontinuation for adverse effects ran at 10.6% on erenumab against 38.9% on topiramate. She is not an extrapolation from that trial — HER-MES enrolled patients with four or more migraine days a month who were preventive-naive or had failed no more than three prior agents, and she has ten migraine days and has never taken one. Its tolerability finding describes her directly, which is rarer than it sounds and is most of why the guideline argument has force here. Her plan’s prior-authorization criteria predate that shift and require two documented eight-week trials of generic preventives first. Sixteen weeks is the floor, and at eighteen headache days a month, sixteen weeks of qualifying costs her somewhere near sixty-five headache days — a price the criteria never priced, because they were written in units of drugs tried rather than days lost.
First preventive visit, working around two contraindications at once
I want to start her on a CGRP monoclonal antibody today, not after two failed generics. The 2024 AHS consensus put this class first-line for a reason, and HER-MES gives us real numbers behind it — erenumab against topiramate head-to-head, with discontinuation for adverse effects running at roughly a quarter of topiramate’s rate. That trial wasn’t run on a patient with her specific history, but her history is exactly the profile it predicts will struggle most on the older drug.
Propranolol is the other standard first option, and I don’t think it’s a reasonable one to offer first here either — beta-blockade worsening depression is documented, not speculative, in a patient three years into a remission she worked to get.
I’m not disputing either contraindication, and I agree neither older drug is a good fit for her. What I’d put in front of her today is candesartan — Tronvik's placebo-controlled trial at 16mg is smaller and older than anything in the CGRP literature, but it is real evidence, and the drug shares neither of her two problems: no depression signal, no cognitive burden.
The trial data favors the CGRP mAb on paper. But her plan requires two documented 8-week failures first, and a prior authorization for a genuine exception can take weeks she doesn’t have with eighteen headache days a month. Candesartan gets her an actually-covered, actually-tolerable treatment starting this week.
Both of you are answering different parts of the same problem, and I don’t think we have to pick one. Her two documented contraindications — named, specific, in her chart — are exactly the basis most plans accept for a step-therapy exception. I’ll file that appeal today.
In the meantime, candesartan starts this week, not instead of the CGRP mAb but ahead of it, so she has something working while the appeal moves. If it clears, we switch. If it doesn’t, we’ve at least given her real, if smaller, evidence-based coverage in the interval rather than eighteen more headache days waiting on paperwork.
Agreed: candesartan started today, CGRP monoclonal antibody prior authorization filed the same visit citing both documented contraindications as the medical-necessity basis for a step-therapy exception, follow-up in four weeks to assess candesartan’s effect and check the appeal’s status.
Switch to the CGRP monoclonal antibody at that point, regardless of how candesartan is doing — the guideline-preferred option becomes accessible and nothing about waiting changes that preference.
Continue candesartan and reassess; the Headache Medicine Specialist and Clinical Pharmacologist did not agree in advance on whether a second appeal is worth pursuing or whether candesartan’s own response should settle the question at that point.